As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.

As demand for immunoglobulin therapies grows across rare autoimmune diseases, manufacturers must expand plasma fractionation capacity while maintaining strict GMP and viral safety standards. This case study shows how Boccard delivered a large-scale, integrated immunoglobulin production facility designed to support long-term IVIg supply.